ASNC2026 to feature three Phase 3 cardiac amyloidosis studies

The American Society of Nuclear Cardiology will spotlight late-stage trial data on cardiac amyloidosis diagnosis and treatment at its Sept. 16-19 meeting in Las Vegas. The session will include Phase 3 results on two amyloid PET approaches and the largest ATTR-CM trial to date.

Why it matters: - Cardiac amyloidosis is a difficult-to-diagnose disease that can affect both imaging strategy and treatment decisions. - The three Phase 3 studies at ASNC2026 cover the full continuum of care, from detecting amyloid deposits to treating transthyretin amyloid cardiomyopathy. - The data could influence how clinicians identify cardiac amyloidosis and how they manage ATTR-CM.

What happened: - The American Society of Nuclear Cardiology will present new Phase 3 findings at its 31st Annual Scientific Session and Exhibition, ASNC2026, Sept. 16-19 in Las Vegas. - The Late-Breaking Clinical Science session is scheduled for Thursday, Sept. 17, at 1:30 p.m. Pacific Time. - The session will include presentations from three pivotal studies: REVEAL, CARDIAG and CARDIO-TTRansform. - ASNC President Jamieson M. Bourque said the studies show momentum in cardiac amyloidosis imaging and treatment.

The details: - REVEAL will be presented by Sharmila Dorbala, MD, MPH, MASNC. - REVEAL evaluated I-124 evuzamitide PET/CT for the diagnosis of cardiac amyloidosis. - The open-label, multicenter study enrolled 170 adults with suspected cardiac amyloidosis at 18 U.S. centers. - Participants included patients with suspected AL, ATTR and other forms of amyloidosis. - The study used cardiac and partial-body PET/CT imaging after evuzamitide administration. - Independent cardiac PET/CT experts reviewed images and compared them with an adjudicated standard-of-care diagnosis using clinical, laboratory, imaging, biopsy and genetic data. - ASNC2026 will include the trial’s sensitivity and specificity results. - CARDIAG will be presented by Paco E. Bravo, MD. - CARDIAG evaluated F-18 florbetaben PET in AL cardiac amyloidosis. - Amyloid-targeted PET is designed to visualize amyloid fibrils directly, unlike conventional cardiac imaging, which generally shows the structural and functional consequences of amyloid deposition. - CARDIAG includes exploratory analyses on whether quantitative PET can distinguish AL from ATTR cardiac amyloidosis and detect extracardiac amyloid deposition. - The presentation will also compare imaging characteristics of F-18- and I-124-labeled amyloid-targeting compounds. - CARDIO-TTRansform will be presented by Brett W. Sperry, MD, FASNC. - CARDIO-TTRansform evaluated eplontersen in patients with transthyretin amyloid cardiomyopathy. - Eplontersen is an antisense oligonucleotide that reduces hepatic production of transthyretin, or TTR. - The randomized, double-blind, placebo-controlled Phase 3 trial enrolled 1,432 patients with wild-type or variant ATTR-CM at 130 centers in 20 countries. - Patients received eplontersen or placebo every four weeks for 140 weeks, on top of standard care. - More than half of participants were receiving a TTR stabilizer at baseline. - ASNC2026 will feature efficacy and safety results for the primary composite endpoint of cardiovascular mortality and recurrent cardiovascular events. - The presentation will also cover functional, quality-of-life and mortality outcomes. - Analyses will examine the overall population, patients on TTR stabilizers and patients who received eplontersen without baseline stabilizer therapy.

Between the lines: - The REVEAL and CARDIAG studies suggest amyloid PET is moving toward more direct and disease-specific imaging. - CARDIO-TTRansform reflects growing interest in combining TTR gene silencing with existing therapies. - With 1,432 patients, CARDIO-TTRansform is the largest ATTR-CM trial to date. - ASNC is using the late-breaking session to position nuclear cardiology at the center of emerging amyloidosis care.

What's next: - Researchers will present the full late-breaking data during ASNC2026 in Las Vegas. - The conference will also cover cardiac PET and SPECT, artificial intelligence, innovative tracers, amyloidosis, inflammation and next-generation imaging technologies. - ASNC2026 will offer virtual registration alongside in-person attendance.

The bottom line: - ASNC2026 is set to deliver a major readout on where cardiac amyloidosis diagnosis and treatment are headed, with late-stage data spanning imaging and therapy.